Popular

• 

  RestartResume

  Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies

  MinuteCE®

  Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies

  • 

    

    Jaffer Ajani, MD

    Peer

  0.75 program credits

• 

  RestartResume

  The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC

  MinuteCE®

  The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC

  • 

    

    Harry Yoon, MD

    Peer

  0.75 program credits

• 

  MinuteCE®

  Clinical Conundrums in ARIA: Navigating Case Scenarios in Your Own Practice Setting

  • 

    

    James R. Bateman, MD, MPH

    Peer

  • 

    

    Jerome A. Barakos, MD

    Peer

  • 

    

    Danya Khoujah, MBBS, MEHP, FACEP, FAAEM

    Peer

  • 

    

    B. Joy Snider, MD, PhD

    Peer

  • 

    

    Charles P. Vega, MD

    Peer

  1.25 credits 11 episodes

• 

  RestartResume

  Reducing the Risk of Postpartum Depression Through Sleep Interventions

  Advances in Women's Health

  Reducing the Risk of Postpartum Depression Through Sleep Interventions

  • 

    

    Nicole Leistikow, MD

    Peer

• 

  RestartResume

  Vorasidenib and mIDH Gliomas: Reviewing the Efficacy Data

  NeuroFrontiers

  Vorasidenib and mIDH Gliomas: Reviewing the Efficacy Data

  • 

    

    Jennie Taylor, MD

    Peer

• 

  RestartResume

  Improving the Detection and Prevention of PPD: The Potential Role of Biomarkers

  Advances in Women's Health

  Improving the Detection and Prevention of PPD: The Potential Role of Biomarkers

  • 

    

    Ashley Baker, MSN, PMHNP

    Peer

  • 

    

    Lauren Osborne, MD

    Peer

• 

  RestartResume

  HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)

  Project Oncology®

  HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)

  • 

    

    Fernando López-Ríos, MD, PhD

    Peer

  • 

    

    Christian Rolfo, MD, PhD

    Peer

  • 

    

    Charlie Gourley, MD, PhD

    Peer

• 

  RestartResume

  Three months of DAPT after PCI

  ACC Action Center

  Three months of DAPT after PCI

  • 

    

    Anna Bortnick, MD, PhD

    Peer

• 

  RestartResume

  mIDH Gliomas Explained: Characteristics and Management Strategies

  NeuroFrontiers

  mIDH Gliomas Explained: Characteristics and Management Strategies

  • 

    

    Jennie Taylor, MD

    Peer

• 

  RestartResume

  AI model may accelerate risk stratification of coronary revascularization in ED

  ACC Action Center

  AI model may accelerate risk stratification of coronary revascularization in ED

  • 

    

    Wayne Batchelor, MD

    Peer

• 

  RestartResume

  Low-dose apixaban noninferior to full dose in cancer-associated VTE

  ACC Action Center

  Low-dose apixaban noninferior to full dose in cancer-associated VTE

  • 

    

    Diego Sadler, MD

    Peer

• 

  RestartResume

  Managing Occasional Constipation: The Role of PEG 3350

  Medical Industry Feature

  Managing Occasional Constipation: The Role of PEG 3350

  • 

    

    Darren Brenner, MD

    Peer

• 

  RestartResume

  Effective Monitoring and Management of Adverse Effects in Metastatic ESCC

  MinuteCE®

  Effective Monitoring and Management of Adverse Effects in Metastatic ESCC

  • 

    

    Harry Yoon, MD

    Peer

  • 

    

    Jaffer Ajani, MD

    Peer

  0.75 program credits

• 

  RestartResume

  Reducing Prostate Cancer Cell Production: The Role of Bipolar Androgen Therapy

  On the Frontlines of Prostate Cancer

  Reducing Prostate Cancer Cell Production: The Role of Bipolar Androgen Therapy

  • 

    

    Mohit Khera, M.D., M.B.A., M.P.H.

    Peer

• 

  MinuteCE®

  Advances in Hemophilia Treatment: Perspectives From Your Colleagues

  • 

    

    Stephanie Ambrose, DO

    Peer

  • 

    

    Jenny McDaniel, MD

    Peer

  1.25 credits 10 episodes